Alterity Therapeutics Limited (PRNAF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -19.6 Million AUD | -5.82% |
| 2023 | -18.52 Million AUD | -3.71% |
| 2022 | -17.85 Million AUD | -23.11% |
| 2021 | -14.5 Million AUD | -39.31% |
| 2020 | -10.41 Million AUD | 18.09% |
| 2019 | -12.71 Million AUD | -19.66% |
| 2018 | -10.62 Million AUD | -54.39% |
| 2017 | -6.88 Million AUD | 19.86% |
| 2016 | -8.58 Million AUD | 17.72% |
| 2015 | -10.43 Million AUD | 16.86% |
| 2014 | -12.55 Million AUD | -60.89% |
| 2013 | -7.8 Million AUD | -46.69% |
| 2012 | -5.31 Million AUD | 15.27% |
| 2011 | -6.27 Million AUD | -28.08% |
| 2010 | -4.9 Million AUD | 40.87% |
| 2009 | -8.28 Million AUD | 34.91% |
| 2008 | -12.73 Million AUD | -15.86% |
| 2007 | -10.99 Million AUD | 3.71% |
| 2006 | -11.41 Million AUD | 3.34% |
| 2005 | -11.8 Million AUD | -32.82% |
| 2004 | -8.88 Million AUD | -134.4% |
| 2003 | -3.79 Million AUD | 24.08% |
| 2002 | -4.99 Million AUD | -66.47% |
| 2001 | -3 Million AUD | -774.45% |
| 2000 | -343.17 Thousand AUD | -328.97% |
| 1999 | -80 Thousand AUD | -11494.2% |
| 1998 | -690.00 AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -8.51 Million AUD | -157.3% |
| 2024 Q1 | -3.31 Million AUD | 57.4% |
| 2024 FY | -23.62 Million AUD | -27.52% |
| 2024 Q4 | -15.1 Million AUD | 0.0% |
| 2024 Q3 | -6.49 Million AUD | 23.8% |
| 2023 Q4 | -7.77 Million AUD | -148.88% |
| 2023 Q3 | -3.12 Million AUD | 70.95% |
| 2023 FY | -18.52 Million AUD | -3.71% |
| 2023 Q1 | -4.19 Million AUD | 59.91% |
| 2023 Q2 | -10.74 Million AUD | -156.27% |
| 2022 Q2 | -10.16 Million AUD | -160.45% |
| 2022 Q4 | -10.46 Million AUD | -171.8% |
| 2022 Q3 | -3.84 Million AUD | 62.12% |
| 2022 Q1 | -3.9 Million AUD | 60.49% |
| 2022 FY | -17.85 Million AUD | -23.11% |
| 2021 Q1 | -3.87 Million AUD | 38.32% |
| 2021 Q3 | -4.21 Million AUD | 56.32% |
| 2021 FY | -14.5 Million AUD | -39.31% |
| 2021 Q4 | -9.87 Million AUD | -134.53% |
| 2021 Q2 | -9.64 Million AUD | -148.56% |
| 2020 FY | -10.41 Million AUD | 18.09% |
| 2020 Q4 | -6.28 Million AUD | -54.36% |
| 2020 Q1 | -2.89 Million AUD | 75.19% |
| 2020 Q2 | -7.59 Million AUD | -162.78% |
| 2020 Q3 | -4.07 Million AUD | 46.38% |
| 2019 Q3 | -3.59 Million AUD | -28.25% |
| 2019 Q4 | -11.65 Million AUD | -224.17% |
| 2019 FY | -12.71 Million AUD | -19.66% |
| 2019 Q2 | -2.8 Million AUD | 0.0% |
| 2019 Q1 | -2.8 Million AUD | -8.02% |
| 2018 FY | -10.62 Million AUD | -54.39% |
| 2018 Q1 | -1.5 Million AUD | -9.97% |
| 2018 Q4 | -2.59 Million AUD | 0.0% |
| 2018 Q3 | -2.59 Million AUD | -72.61% |
| 2018 Q2 | -1.5 Million AUD | 0.0% |
| 2017 Q2 | -2.07 Million AUD | 0.0% |
| 2017 FY | -6.88 Million AUD | 19.86% |
| 2017 Q4 | -1.36 Million AUD | 0.0% |
| 2017 Q3 | -1.36 Million AUD | 34.09% |
| 2017 Q1 | -2.07 Million AUD | 6.01% |
| 2016 Q3 | -2.2 Million AUD | -5.73% |
| 2016 Q2 | -2.08 Million AUD | 0.0% |
| 2016 Q1 | -2.08 Million AUD | 31.4% |
| 2016 Q4 | -2.2 Million AUD | 0.0% |
| 2016 FY | -8.58 Million AUD | 17.72% |
| 2015 FY | -10.43 Million AUD | 16.86% |
| 2015 Q3 | -3.04 Million AUD | -34.54% |
| 2015 Q4 | -3.04 Million AUD | 0.0% |
| 2015 Q2 | -2.26 Million AUD | 0.0% |
| 2015 Q1 | -2.26 Million AUD | 3.47% |
| 2014 Q2 | -3.91 Million AUD | 0.0% |
| 2014 Q4 | -2.34 Million AUD | 0.0% |
| 2014 FY | -12.55 Million AUD | -60.89% |
| 2014 Q3 | -2.34 Million AUD | 40.22% |
| 2014 Q1 | -3.91 Million AUD | -117.5% |
| 2013 Q3 | -1.8 Million AUD | 0.0% |
| 2013 FY | -7.8 Million AUD | -46.69% |
| 2013 Q4 | -1.8 Million AUD | 0.0% |
| 2012 FY | -5.31 Million AUD | 15.27% |
| 2011 FY | -6.27 Million AUD | -28.08% |
| 2010 FY | -4.9 Million AUD | 40.87% |
| 2009 FY | -8.28 Million AUD | 34.91% |
| 2008 Q2 | -3.71 Million AUD | -3026.35% |
| 2008 FY | -12.73 Million AUD | -15.86% |
| 2008 Q4 | -13.1 Million AUD | -11144.72% |
| 2008 Q3 | 118.66 Thousand AUD | 103.19% |
| 2008 Q1 | 127 Thousand AUD | 101.12% |
| 2007 FY | -10.99 Million AUD | 3.71% |
| 2007 Q4 | -11.36 Million AUD | -8504.24% |
| 2007 Q3 | 135.2 Thousand AUD | 103.64% |
| 2007 Q2 | -3.71 Million AUD | -3237.39% |
| 2007 Q1 | 118.3 Thousand AUD | 100.99% |
| 2006 Q2 | -2.68 Million AUD | -1337.85% |
| 2006 Q1 | 217.29 Thousand AUD | 101.57% |
| 2006 Q3 | 190.67 Thousand AUD | 107.09% |
| 2006 Q4 | -11.98 Million AUD | -6385.63% |
| 2006 FY | -11.41 Million AUD | 3.34% |
| 2005 Q2 | -2.48 Million AUD | -463.44% |
| 2005 FY | -11.8 Million AUD | -32.82% |
| 2005 Q1 | 684.35 Thousand AUD | 106.46% |
| 2005 Q4 | -13.82 Million AUD | -2270.86% |
| 2005 Q3 | 637 Thousand AUD | 125.61% |
| 2004 Q4 | -10.59 Million AUD | -1853.18% |
| 2004 FY | -8.88 Million AUD | -134.4% |
| 2004 Q1 | 561.87 Thousand AUD | 111.7% |
| 2004 Q2 | -1.95 Million AUD | -447.36% |
| 2004 Q3 | 604.41 Thousand AUD | 130.97% |
| 2003 FY | -3.79 Million AUD | 24.08% |
| 2003 Q2 | -1.56 Million AUD | -747.46% |
| 2003 Q1 | 242.4 Thousand AUD | 0.0% |
| 2003 Q3 | 574.13 Thousand AUD | 136.58% |
| 2003 Q4 | -4.8 Million AUD | -936.43% |
| 2002 FY | -4.99 Million AUD | -66.47% |
| 2001 FY | -3 Million AUD | -774.45% |
| 2000 FY | -343.17 Thousand AUD | -328.97% |
| 1999 FY | -80 Thousand AUD | -11494.2% |
| 1998 FY | -690.00 AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Evofem Biosciences, Inc. | -17.84 Million USD | -9.832% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -288.577% |
| CSL Limited | 3.7 Billion USD | 100.529% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 123.948% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -2753.44% |
| BioStem Technologies, Inc. | -7.77 Million USD | -151.983% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -1460.646% |
| Qrons Inc. | -643.67 Thousand USD | -2945.271% |
| Nascent Biotech, Inc. | -2.22 Million USD | -779.048% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 64.687% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -194.851% |
| Skye Bioscience, Inc. | -13.67 Million USD | -43.373% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -4617.858% |
| Rebus Holdings, Inc. | -664 Thousand USD | -2852.065% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -23.516% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -1367.819% |
| Genscript Biotech Corporation | -415.79 Million USD | 95.286% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -4931.627% |
| Adynxx, Inc. | - USD | Infinity% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 72.694% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 498.829% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -7389.401% |
| SQZ Biotechnologies Company | -75.82 Million USD | 74.149% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -587.657% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -1176.112% |
| Mesoblast Limited | -84.14 Million USD | 76.705% |
| Marizyme, Inc. | -34.08 Million USD | 42.494% |
| Genus plc | 6.4 Million USD | 406.277% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 301.199% |
| Pharming Group N.V. | -4.87 Million USD | -301.712% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -886.756% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -2004.588% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -134.751% |
| ContraFect Corporation | -56.88 Million USD | 65.544% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -330.36% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -1298.134% |
| IMV Inc. | -38.67 Million USD | 49.312% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -612.572% |
| MultiCell Technologies, Inc. | -722.81 USD | -2711775.735% |
| ONE Bio Corp. | 13.68 Million USD | 243.271% |
| Accustem Sciences Inc. | -3.74 Million USD | -423.212% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 66.771% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -3957.804% |
| Q BioMed Inc. | -3.44 Million USD | -468.888% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 653.721% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -646.015% |
| Biomind Labs Inc. | -1 Million USD | -1841.526% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 64.343% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -575.63% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -951.385% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -65343.74% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -914.261% |
| GB Sciences, Inc. | -1.42 Million USD | -1279.907% |
| Alpha Cognition Inc. | -9.7 Million USD | -101.963% |
| HST Global, Inc. | -140.9 Thousand USD | -13811.097% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -1642.52% |
| Halberd Corporation | -75.05 Thousand USD | -26018.2% |
| Enzolytics Inc. | -2.14 Million USD | -812.217% |
| Agentix Corp. | -1.37 Million USD | -1328.95% |
| Resverlogix Corp. | -12.74 Million USD | -53.751% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -518.687% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 95.388% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -1777.558% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -571.419% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -1141.121% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -475.678% |
| AVAX Technologies, Inc. | 6.69 Million USD | 392.874% |
| Zenith Capital Corp. | -8.94 Million USD | -119.185% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -112417.703% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -698.337% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -11328.932% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -877.76% |
| Kadimastem Ltd | -3.04 Million USD | -544.74% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -1891.936% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -10700.732% |
| LadRx Corporation | -3.82 Million USD | -412.647% |
| Cell Source, Inc. | -4.32 Million USD | -353.182% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -2753.44% |
| NovAccess Global Inc. | -2.46 Million USD | -694.634% |
| Affymax, Inc. | -15.04 Million USD | -30.279% |
| Itoco Inc. | -919.14 Thousand USD | -2032.614% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -362.477% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1651.717% |
| Mobile Lads Corp. | -554.55 Thousand USD | -3434.705% |
| CytoDyn Inc. | -18.05 Million USD | -8.549% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -77777.271% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -8806.71% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -3371.031% |
| SYBLEU INC | -149.18 Thousand USD | -13039.636% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -979.199% |
| International Stem Cell Corporation | -663 Thousand USD | -2856.517% |
| Bioxytran, Inc. | -3.82 Million USD | -413.114% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -37137.289% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -96270.251% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 45.95% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -1111.478% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -2563.873% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -530.077% |
| Neutra Corp. | -229.48 Thousand USD | -8441.571% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -11.761% |
| PureTech Health plc | -146.19 Million USD | 86.592% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 8.792% |
| IXICO plc | -1.43 Million USD | -1264.072% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -106.529% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 83.907% |
| CSL Limited | 3.81 Billion USD | 100.514% |
| Cellectis S.A. | -108.85 Million USD | 81.993% |